Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1990 May;29(5):497–501. doi: 10.1111/j.1365-2125.1990.tb03671.x

Influence of nicardipine on the pharmacokinetics and pharmacodynamics of propranolol in healthy volunteers.

D F Schoors 1, I Vercruysse 1, G Musch 1, D L Massart 1, A G Dupont 1
PMCID: PMC1380147  PMID: 2350528

Abstract

1. The influence of a single oral dose of nicardipine 30 mg on the pharmacokinetics and pharmacodynamics of propranolol 80 mg was investigated in twelve healthy volunteers. 2. Co-administration of nicardipine significantly increased the AUC and the mean Cmax of propranolol. 3. Blood pressure and heart rate tended to decrease more when propranolol and nicardipine were administered together than when propranolol was given alone, but differences are of doubtful significance. 4. The results indicate that nicardipine alters the pharmacokinetics of propranolol by impaired hepatic 'first-pass' clearance, but pharmacodynamics were little affected.

Full text

PDF
497

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bauer L. A., Stenwall M., Horn J. R., Davis R., Opheim K., Greene L. Changes in antipyrine and indocyanine green kinetics during nifedipine, verapamil, and diltiazem therapy. Clin Pharmacol Ther. 1986 Aug;40(2):239–242. doi: 10.1038/clpt.1986.169. [DOI] [PubMed] [Google Scholar]
  2. Evans G. H., Shand D. G. Disposition of propranolol. V. Drug accumulation and steady-state concentrations during chronic oral administration in man. Clin Pharmacol Ther. 1973 Jul-Aug;14(4):487–493. doi: 10.1002/cpt1973144part1487. [DOI] [PubMed] [Google Scholar]
  3. Gangji D., Juvent M., Niset G., Wathieu M., Degreve M., Bellens R., Poortmans J., Degre S., Fitzsimons T. J., Herchuelz A. Study of the influence of nifedipine on the pharmacokinetics and pharmacodynamics of propranolol, metoprolol and atenolol. Br J Clin Pharmacol. 1984;17 (Suppl 1):29S–35S. doi: 10.1111/j.1365-2125.1984.tb02425.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Hanet C., Pouleur H., Harlow B. J., Rousseau M. F. Effects of long-term combined dosing with nicardipine and propranolol on coronary hemodynamics, myocardial metabolism, and exercise tolerance in patients with angina pectoris: comparison with monotherapy. Am Heart J. 1988 Aug;116(2 Pt 1):431–439. doi: 10.1016/0002-8703(88)90615-1. [DOI] [PubMed] [Google Scholar]
  5. Harris L., Dargie H. J., Lynch P. G., Bulpitt C. J., Krikler D. M. Blood pressure and heart rate in patients with ischaemic heart disease receiving nifedipine and propranolol. Br Med J (Clin Res Ed) 1982 Apr 17;284(6323):1148–1151. doi: 10.1136/bmj.284.6323.1148. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Lessem J. N., Barone E. J., Berl T., Detwiler J., Lewin A. T., Lubash G. D., Margolis R., McGowan R. L., Ram C. V., Vlachakis N. Nicardipine and propranolol in the treatment of essential hypertension. Am J Hypertens. 1989 Mar;2(3 Pt 1):146–153. doi: 10.1093/ajh/2.3.146. [DOI] [PubMed] [Google Scholar]
  7. Lynch P., Dargie H., Krikler S., Krikler D. Objective assessment of antianginal treatment: a double-blind comparison of propranolol, nifedipine, and their combination. Br Med J. 1980 Jul 19;281(6234):184–187. doi: 10.1136/bmj.281.6234.184. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Melander A., Danielson K., Scherstén B., Wåhlin E. Enhancement of the bioavailability of propranolol and metoprolol by food. Clin Pharmacol Ther. 1977 Jul;22(1):108–112. doi: 10.1002/cpt1977221108. [DOI] [PubMed] [Google Scholar]
  9. Musch G., Massart D. L. Isolation of basic drugs from plasma using solid-phase extraction with a cyanopropyl-bonded phase. J Chromatogr. 1988 Nov 18;432:209–222. doi: 10.1016/s0378-4347(00)80646-5. [DOI] [PubMed] [Google Scholar]
  10. Packer M. Drug therapy. Combined beta-adrenergic and calcium-entry blockade in angina pectoris. N Engl J Med. 1989 Mar 16;320(11):709–718. doi: 10.1056/NEJM198903163201107. [DOI] [PubMed] [Google Scholar]
  11. Pouleur H., Etienne J., Van Mechelen H., Van Eyll C., Charlier A. A., Brasseur L. A., Rousseau M. F. Effects of nicardipine or nifedipine added to propranolol in patients with coronary artery disease. Postgrad Med J. 1984;60 (Suppl 4):23–28. [PubMed] [Google Scholar]
  12. Shand D. G. Pharmacokinetic properties of the beta-adrenergic receptor blocking drugs. Drugs. 1974;7(1):39–47. doi: 10.2165/00003495-197407010-00003. [DOI] [PubMed] [Google Scholar]
  13. Sorkin E. M., Clissold S. P. Nicardipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in the treatment of angina pectoris, hypertension and related cardiovascular disorders. Drugs. 1987 Apr;33(4):296–345. doi: 10.2165/00003495-198733040-00002. [DOI] [PubMed] [Google Scholar]
  14. Stone P. H., Antman E. M., Muller J. E., Braunwald E. Calcium channel blocking agents in the treatment of cardiovascular disorders. Part II: Hemodynamic effects and clinical applications. Ann Intern Med. 1980 Dec;93(6):886–904. doi: 10.7326/0003-4819-93-6-886. [DOI] [PubMed] [Google Scholar]
  15. Tateishi T., Nakashima H., Shitou T., Kumagai Y., Ohashi K., Hosoda S., Ebihara A. Effect of diltiazem on the pharmacokinetics of propranolol, metoprolol and atenolol. Eur J Clin Pharmacol. 1989;36(1):67–70. doi: 10.1007/BF00561026. [DOI] [PubMed] [Google Scholar]
  16. Zylber-Katz E., Turetz-Abramovitch M., Koren G., Levy M. Pharmacokinetic interaction between nifedipine and propranolol. Fundam Clin Pharmacol. 1988;2(1):29–35. doi: 10.1111/j.1472-8206.1988.tb00618.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES